Wu, Speaking of PFE's Droloxifene and CP133,156, here are some of the players being studied in LGND's tissue specific estrogen program with AHP:
Preclinical studies are ongoing in the USA with Ligand and Wyeth Ayerst
to identify IND candidates from a series of tissue selective estrogen
agonists. These agents may have potential for the treatment of
osteoporosis.
estrogen agonists, Ligand , estrogen agonists, Wyeth Ayerst, M5B, Bone
Calcium Regulators, G3C, Estrogens Excluding G3A, G3E, G3F, Wyeth
Ayerst, new-drug.
estrogen agonists, Ligand , estrogen agonists, Wyeth Ayerst, M5B, Bone
Calcium Regulators, G3C, Estrogens Excluding G3A, G3E, G3F, Ligand
, new-drug. |
